Gliomas Clinical Trial
Official title:
Chronic Convection Enhanced Delivery of Topotecan for Recurrent High Grade Gliomas
Verified date | June 2022 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).
Status | Completed |
Enrollment | 5 |
Est. completion date | August 20, 2021 |
Est. primary completion date | August 20, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have a recurrent malignant glioma (World Health Organization (WHO) grade III-IV), including recurrent glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma. Stereotactic biopsies will be performed to confirm this diagnosis prior to initiating the treatment. - Patients with tumors of the brain must have been previously treated with surgical resection, external beam radiation, and temozolomide chemotherapy. - An magnetic resonance (MR) scan must be obtained within 30 days of enrollment and must demonstrate an enhancing mass without significant mass effect. Tumors must be less than 32 cc in total volume. The lesion must be stereotactically accessible. - Patients must have demonstrated evidence of increasing contrast enhancement on MR or computed tomography (CT) imaging while on stable or increasing dose of steroid. - Karnofsky performance score of greater than or equal to 60. - Men and women of childbearing potential must practice birth control. Women of child bearing potential must have a urine pregnancy test within 7 days of study entry. - Patients must possess the ability to give Informed Consent. - Patients must be willing to and medically capable of undergoing the surgical operation. - There is no upper age limit. Patients at extreme upper end of the age spectrum will not be automatically excluded, but will be carefully scrutinized to determine their suitability for this procedure. - Patients must be at least 18 years old. - Patients must have normal organ and marrow function as defined below: - Leukocytes: =3,000/ cells per microliter of blood (mcL) - Absolute neutrophil count: =1,500/mcL - Platelets: =100,000/mcL - Total bilirubin: within normal institutional limits - aspartate aminotransferase (AST) (SGOT)/alanine aminotransferase (ALT) (SGPT): =2.5 × institutional upper limit of normal - Creatinine: within normal institutional limits OR - Creatinine clearance: =60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. Exclusion Criteria: - Patients with diffuse subependymal or cerebral spinal fluid (CSF) disease. - Patients with tumors involving the cerebellum or both cerebral hemispheres. - Patients with an active infection requiring treatment or having an unexplained febrile illness. - Patients who are known HIV, Hepatitis B or Hepatitis C positive. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with topotecan. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated. - Patients with systemic diseases which may be associated with unacceptable anesthetic/operative risk. - Patients who have previously received systemic topotecan for their tumor - Patients who are not able to receive an MRI scan. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan, other topoisomerase inhibitors or gadolinium compounds. |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Irving Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Jeffrey N. Bruce | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose at which all patients have had no greater than grade 2 adverse reactions | This is designed to measure the safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients. | Up to 29 days | |
Secondary | Clinical toxicity rate | This is defined by the number of serious adverse events occuring, which is projected to be = 5% at 23-29 days. A clinical toxicity rate that exceeds 20% will be considered unacceptable for this procedure. | Up to 29 days | |
Secondary | Change in radiographic tumor response | Tumor response to TPT will be investigated by MRI scan. | Baseline, 6 weeks post-treatment | |
Secondary | Progression free survival (PFS) | The length of time during and after the treatment of disease that a patient lives with the disease but it does not get worse. Patients will be contacted every 3-6 months, up to 5 years, by phone until death. | Every 3-6 months, up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03952598 -
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
|
N/A | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Terminated |
NCT01251913 -
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
|
||
Withdrawn |
NCT01961934 -
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03557359 -
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
|
Phase 2 | |
Recruiting |
NCT01655927 -
Efficacy of Tranexamic Acid in Brain Tumor Resections
|
Phase 3 | |
Completed |
NCT01225003 -
Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas
|
N/A | |
Completed |
NCT01144247 -
Cellular Immunotherapy Study for Brain Cancer
|
Phase 1 | |
Completed |
NCT00967577 -
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT01517776 -
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
|
Phase 2 | |
Completed |
NCT00832598 -
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
|
N/A | |
Completed |
NCT00589706 -
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
|
Phase 2 | |
Withdrawn |
NCT05054400 -
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
|
Early Phase 1 | |
Recruiting |
NCT03091270 -
ZOOMit-fMRI Identifies Motor Functional Cortex
|
||
Completed |
NCT00200161 -
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
|
Phase 2 | |
Terminated |
NCT02332889 -
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
|
Phase 1/Phase 2 | |
Recruiting |
NCT05804227 -
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
|
Early Phase 1 |